BioSpace News Archive

Nonsurgical aesthetic procedures are either minimally-invasive or non-invasive procedures. Nonsurgical aesthetic procedures are not permanent and need to be repeated over a period of time to maintain the results or effects.

Key components driving the global safety needles market are ascend in accentuation on counteractive action of needlestick wounds and broad utilization of prefilled syringes.

The global CAR-T cell therapy market is set to chart stellar growth owing to an impressive CAGR between 2018 and 2028.

Merck KGaA, Darmstadt, Germany, a leading science and technology company, has moved its Silicon Valley Innovation Hub team to San Jose’s Intermolecular’s 150,000 sqft facility, creating a unique space for innovation and collaboration at the intersection of life science, healthcare and electronic materials.

Mind Cure Health Inc. a leader in developing technology to advance psychedelic-related treatments, is pleased to announce that the Company’s bioinformatics platform, PsyCollage, has identified opportunities for ibogaine to support neuroregenerative pathways that the Company believes could be pivotal in treating neuropathic pain and brain trauma.

Abcam, a global innovator in life science reagents and tools, announced the expansion of its footprint in China with the opening of new custom-built facilities in Hangzhou and Shanghai.

The upcoming Phase III trial with Diamyd® in new-onset type 1 diabetes will be based on the first precision medicine approach in the field.

As in-class learning has been affected in much of the country due to the COVID-19 pandemic, the Government of Canada, through its COVID-19 Immunity Task Force, is supporting three research projects that will estimate how many teachers and school personnel have been infected with SARS-CoV-2, the virus that causes COVID-19.

Mallinckrodt plc, a global biopharmaceutical company, today announced publication of results from its pivotal Phase 3 CONFIRM study to assess the efficacy and safety of its investigational agent terlipressin in adults with hepatorenal syndrome type 1 (HRS-1

AIM ImmunoTech Inc. (NYSE American: AIM) today announced that Thomas K. Equels, Chief Executive Officer of AIM ImmunoTech, will be presenting at the H.C. Wainwright Life Sciences Conference to be held virtually between March 9-10, 2021.